LF

MVDr. Emília Hijová, PhD.   SK

Email:
emilia.hijova@upjs.sk
Homepage:
https://www.upjs.sk/LF/zamestnanec/emilia.hijova
Faculty:
LF UPJŠ - Pavol Jozef Šafárik University in Košice Faculty of Medicine
Department:
CKPV - Center of Clinical and Preclinical Research MEDIPARK
Office:
MB6O20
Phone:
+421 55 234 3463
ORCID ID:
0000-0002-8259-373X
MVDr. Emília Hijová, PhD works as a researcher with scientific qualification level IIa in the Center for Clinical and Preclinical Research (MEDIPARK) - Department of Experimental Medicine, Faculty of Medicine, UPJŠ in Košice. She is a specialist in Normal and Pathological Physiology. As a researcher, she focuses on the use of probiotic microorganisms and substances of natural origin in the prevention and therapy of diseases. She solves the problem of changes in selected parameters of the digestive tract during the metabolic process. She was the supervisor of 4 diploma theses and the supervisor-specialist of 1 doctoral student. He participates in solving several research projects (AV, VEGA, APVV, SF EU). She is the author or co-author of more than 295 original scientific and professional papers (27 CC, WoS or Scopus) published in domestic and foreign journals and monographs, which have been cited more than 690 times in the WoS and Scopus citation indexes (HI-13).

Higher education and further qualification growth
Second degree of higher education:
University of Veterinary Medicine and Pharmacy in Košice, 1989, Food Hygiene
Third degree of higher education:
Pavol Jozef Šafárik University in Košice, Faculty of Medicine, Department of Experimental Medicine, 2005, Normal and pathological physiology
Associate professor:
Pavol Jozef Šafárik University in Košice, Faculty of Medicine, scientific-professional degree IIa, 2010, Normal and pathological physiology

Research /art/ teacher profile

Display details  
Selected publications

Hijová, E., Bertková, I., Benetinová, V.: Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective. Biomedicines, 2026,14,6, 1267 (1-27). IF-4,5; Q1

Hijová, E., Bertková, I., Štofilová, J.: Incorporating Postbiotics into Intervention for Managing Obesity, International Journal of Molecular Sciences, 2025,26,11,5326 (1-23). IF-5,6; Q1

Hijová, E. Probiotic in IBD : Evidence and Perspectives on Patient Health and Disease Management. International Journal of Molecular Sciences, 2025,16,18,9065 (1-26). IF-5,6; Q1

Hijová, E.:   Postbiotics as Metabolites and Their Biotherapeutic Potential, International Journal of Molecular Sciences, 2024,25,10,5441 (1-22), IF-4,9; Q1

Hijová, E.: Benefits of biotics for cardiovascular disesaes. International Journal of Molecular Sciences, 2023,24,7,6292 (1-18). IF-4,9; Q1

Selected projects

NFP401101C030-PERBIOKARDIO

Inovatívny prístup vo výskume črevného mikrobiómu a vývoji personalizovaných probiotík pre pacientov s kardiovaskulárnymi ochoreniami.

Zodpovedný riešiteľ: RNDr. Jana Štofilová, PhD.

An innovative approach to gut microbiome research and the development of personalized probiotics for patients with cardiovascular diseases.

Principal Investigator: RNDr. Jana Štofilová, PhD.

APVV-23-0354

Personalizovaný prístup k selekcii a aplikácii efektívnych probiotík a synbiotík v manažmente obezity.

Zodpovedný riešiteľ: RNDr. Izabela Bertková, PhD.

Personalized approach to the selection and application of effective probiotics and synbiotics in obesity management.

Principal Investigator: RNDr. Izabela Bertková, PhD.

APVV-23-0031

Transplantácia fekálnej mikrobioty a jej potenciálne využitie pri nešpecifických zápalových ochoreniach čriev v humánnej a veterinárnej medicíne.

Zodpovedný riešiteľ: MVDr. Soňa Gancarčíková, PhD.

Fecal microbiota transplantation and its potential application in inflammatory bowel diseases in human and veterinary medicine.

Principal Investigator: MVDr. Soňa Gancarčíková, PhD.

VEGA -1/0253/25

Inovatívny prístup v terapii črevných zápalových ochorení-cielené probiotiká a synbiotiká.

Zodpovedný riešiteľ: RNDr. Jana Štofilová, PhD.

An innovative approach to the therapy of inflammatory bowel diseases – targeted probiotics and synbiotics.

Principal Investigator: RNDr. Jana Štofilová, PhD.

VEGA -1/0232/25

Predklinický molekulárno-biologický výskum účinku probiotík a synbiotík na báze Limosilactobacillus fermentum na cielenú podporu funkčnosti črevnej bariéry.

Zodpovedný riešiteľ: RNDr. Anna Kamlárová, PhD.

Preclinical molecular-biological research on the effects of probiotics and synbiotics based on *Limosilactobacillus fermentum* for the targeted support of intestinal barrier function.

Principal Investigator: RNDr. Anna Kamlárová, PhD.

Additional information

Projects
Project of Structural Funds EU: Drive4SIFood (ITMS 2014+ 313011V336) Demand-driven research for sustainable and innovative food (2019-2023) PROBIO-3 (ITMS 313011T651) Bioactive substances for health promotion and prevention of chronic diseases (2016-2019) PROBIO (ITMS 26220220104) Probiotic microorganisms and bioactive substances of natural origin for a healthier population of Slovakia (2011-2015) PROBIOTECH (ITMS 26220220152) Competence Center for Biomodulators and Nutritional Supplements (2011-2015) CEMIO (ITMS 26220120058) Center of Excellence for Health Factors Research Focusing on a Group of Marginalized and Immunocompromised People (2010-2013)

LF